Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
They are hopeful to see their new weight loss medication (anti-obesity medication) approved this year, hopefully this Fall
Tirzepatide had finished its last Phase 3 clinical trial SURPASS-5 in February 2022, 50 and it favors activating GIPR (for GIPR, native GIP EC 50 : 0.0334nM, tirzepatide EC 50 : 0.0224nM
By inhibiting NNMT, 5Amino1MQ Peptide reshapes the metabolic phenotype of adipose tissue, promotes lipolysis, increases energy expenditure, and restores dynamic balance of fat metabolism - one of its core weightloss mechanisms
The aim is to enable clinicians to identify such disorders at an early stage and improve the prognosis of patients
